Landing
International Congress on Hematologic Malignancies (HEM) 2022
Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 PRINCE Study
Pegcetacoplan Patient Compliance Rates In PEGASUS And PRINCE Phase 3 Trials Compared To Published Oral Medication Compliance Rates In Literature
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.